CAMBRIDGE, Mass., Jan. 4 /PRNewswire/ -- Archemix Corp. announced today that Dr. Errol De Souza, Archemix's President and Chief Executive Officer, will present at the 25th Annual JPMorgan Healthcare Conference in San Francisco, California on Thursday, January 11, 2007 at 11:00 a.m. (PST). In his presentation, Dr. De Souza will provide an update of Archemix's product portfolio -- including the commencement of a Phase I clinical trial for the company's ARC1779 aptamer -- strategic and business initiatives and goals for 2007.
About Aptamers
Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low toxicity and immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed, offering a significant cost advantage.
About Archemix Corp.
Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The company's mission is to develop aptamers as a class of directed therapeutics for the prevention and treatment of human disease. Because of their unique properties and proven efficacy, aptamers offer an alternative to biologics and small molecules in numerous applications and offer the potential to be a major class of drugs for the treatment of unmet medical needs.
Archemix's aptamer expertise is complemented by a robust patent estate comprised of over 220 issued and 230 pending patents covering the identification, composition, and use of therapeutic aptamers. In addition to the company's core aptamer generation technology, Archemix possesses strong expertise in both pre-clinical and clinical drug development. Further information on Archemix can be found at www.archemix.com.
For more information about Archemix or aptamers, or to speak with Dr. Errol De Souza, please contact Davia Temin or Suzanne Oaks at or .
SOURCE Archemix Corp.